Physician profile
John E Walker
NPI 1114959301
$3,767.82
in general payments reported to CMS, 2019-2025
39 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $378 · 2021: $390 · 2022: $792 · 2023: $806 · 2024: $320 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $953.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $482.53 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $242.42 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $241.10 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $226.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.63 | 2019-2025 | Jardiance |
| Abbott Laboratories | $186.01 | 2019-2025 | Eterna, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $147.46 | 2019-2023 | Shingrix |
| Seqirus USA INC | $120.06 | 2021-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $85.98 | 2021-2022 | |
| Amgen INC. | $85.32 | 2022-2025 | Otezla, Repatha, Otezla |
| Radius Health, INC. | $79.27 | 2023 | Tymlos |
| Sanofi Pasteur INC. | $77.63 | 2019-2022 | |
| Hologic Sales and Service, LLC | $58.52 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Lucid Diagnostics INC. | $53.01 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.